The FDA has not formally studied this combination in controlled trials, so evidence comes from case reports and clinical experience rather than large randomized studies
There were no differences in HbA1c, lipid status or BMI changes between diets
In a major trial, participants on Mounjaro had greater A1C reductions and more people reached target A1C levels compared with those on semaglutide
In many cases, learning sustainable patterns with healthy eating and activity habits may lead to more lasting results without the need for ongoing drug therapy
The treatment with GLP-1based therapies, which mediates a decrease in blood glucose and body weight, may inhibit cancer growth and progression [15]
We acknowledge that there were some differences in the comparison between GLP-1RAs and other glucose-lowering agents, particularly concerning HbA 1c levels, the use of insulin and the use of SGLT2 inhibitors, which may have influenced the results